Zvast Biotechnology
Pancreatic Cancer
Pan02 is a murine pancreatic ductal adenocarcinoma cell line derived from C57BL/6 mouse pancreatic tissue induced by chemical carcinogen. This cell line retains key pathological features of human pancreatic cancer, including dense desmoplastic stroma, strong invasiveness and low immunogenicity. The subcutaneous xenograft model established by Pan02 cells is a widely used syngeneic preclinical in vivo model for pancreatic cancer research, extensively applied in anti-tumor drug screening, immunotherapy evaluation, tumor stroma and immune microenvironment research. Different from human tumor xenograft models, syngeneic Pan02 model is constructed on immunocompetent C57BL/6 mice, which can preserve intact murine immune system. The model has stable tumor formation, controllable growth rate and convenient real-time tumor volume measurement, suitable for large-scale in vivo pharmacodynamic screening of anti-pancreatic cancer agents.
Pan02 cells originate from C57BL/6 mouse, so the syngeneic recipient mice have no immune rejection against Pan02 tumor cells. After harvesting Pan02 cells in logarithmic growth phase and preparing cell suspension, the suspension is subcutaneously inoculated into the dorsal flank of C57BL/6 mice. Tumor cells continuously proliferate in subcutaneous tissue and eventually form solid tumor masses. Regular recording of tumor volume, body weight and survival status of mice enables assessment of in vivo tumor growth kinetics and quantitative analysis of anti-tumor efficacy of test compounds or biological agents.
We're here to help! Whether you have questions about our products, need support, or want to share feedback, we'd love to hear from you. Please reach out through any of the methods below, and our team will get back to you as soon as possible.
